BIOTECHNOLOGY VALUE FUND L P 13D/13G Filings for Regulus Therapeutics Inc. (RGLS)

BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Regulus Therapeutics Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-02-14
1:05 pm
Purchase		 2021-12-31 13G Regulus Therapeutics Inc.
RGLS		 BIOTECHNOLOGY VALUE FUND L P 966,124
9.990%		 261,077increase
(+37.03%)		 Filing
2021-02-12
7:23 pm
Purchase		 2020-12-31 13G Regulus Therapeutics Inc.
RGLS		 BIOTECHNOLOGY VALUE FUND L P 705,046
9.990%		 495,376increase
(+236.26%)		 Filing